Smoking and outcomes following personalized antiplatelet therapy in chronic coronary syndrome patients: A sub study from the randomized PATH‐PCI trial
Key Points:
- Analyzes the effect of smoking on personalized antiplatelet therapy outcomes.
- Utilizes data from the PATH-PCI trial in chronic coronary syndrome patients.
- Aims to refine treatment approaches based on smoking status to improve cardiovascular outcomes.
Description
This substudy of the randomized PATH-PCI trial investigates the impact of smoking on outcomes in chronic coronary syndrome patients receiving personalized antiplatelet therapy. It examines whether smoking status influences treatment efficacy and cardiovascular risk, aiming to optimize antiplatelet strategies for different patient profiles.
Be the first to review “Smoking and outcomes following personalized antiplatelet therapy in chronic coronary syndrome patients: A sub study from the randomized PATH‐PCI trial”
Reviews
There are no reviews yet.